Renalytix Plc (2O9.F)
| Previous Close | 0.2620 |
| Open | 0.2660 |
| Bid | 0.3120 x N/A |
| Ask | 0.3480 x N/A |
| Day's Range | 0.2660 - 0.2940 |
| 52 Week Range | 0.1110 - 1.6300 |
| Volume | |
| Avg. Volume | 83 |
| Market Cap | 38.855M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings Date | Feb 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRenalytix Announces Financing with Expected Size of up to $4 Million
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas
- GlobeNewswire
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce riskLONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024. In the release of the n
- GlobeNewswire
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today’s report of financial results regarding the date and time of its conference call and webcast to discuss
